Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · evidence extract

GHK-Cu in cutaneous wound healing and tissue repair — evidence extract

The Institute's graded assessment of GHK-Cu for cutaneous wound healing and tissue repair, with the contributing trials and the domain-by-domain certainty reasoning.

Document identifier
CEI-MN-033/EV-WOUND-HEALING
Series
Evidence extract
Version
3.0
Published
08 Jan 2026
Last reviewed
08 Jan 2026
Next review
08 Jan 2028
Identifier
10.71829/cei.mono.33
Certainty
Low
Cycle
2026 Q1

§1Evidence extract: Cutaneous wound healing and tissue repair

§1.1Question and anchor outcome

Population
Restoration of epithelial and dermal integrity following injury, assessed by closure rate, area reduction and scar quality.
Intervention
GHK-Cu, topical in cosmetic and dermatological use; subcutaneous in research contexts
Comparator
As used in each contributing trial; reported per trial rather than pooled across comparator types
Anchor outcome
Time to complete closure

Additional outcomes the Institute extracts for this indication: Percentage area reduction; Scar assessment scale; Infection rate.

§1.2Contributing trials

Table 1. Trials contributing to the assessment of GHK-Cu in cutaneous wound healing and tissue repair.

TrialPhaseDesignRandomisedDurationYear
GHKCU-TOPICAL-12Randomised, double-blind, placebo-controlled12 weeks2005
GHKCU-TOPICAL-22Randomised, double-blind, placebo-controlled12 weeks2007

§1.3Certainty assessment

Certainty assessment by domainDowngrading decision recorded for each certainty domain.Certainty domainNo concernSeriousVery seriousEffect on ratingRisk of biasno downgradeInconsistencyno downgradeIndirectnessno downgradeImprecisionno downgradePublication biasdowngrade two levelsTotal downgrading: 2 levelsLow certainty
Figure 2. Domain-by-domain certainty assessment for GHK-Cu in cutaneous wound healing and tissue repair. The starting rating for a body of randomised evidence is high; each serious concern reduces it by one level and each very serious concern by two.

Table 2. Reasoning recorded against each certainty domain.

DomainRatingReasoning
Risk of biasNo concernNo serious concern identified in this domain.
InconsistencyNo concernNo serious concern identified in this domain.
IndirectnessNo concernNo serious concern identified in this domain.
ImprecisionNo concernNo serious concern identified in this domain.
Publication biasVery seriousToo few contributing studies for a formal assessment; the risk cannot be excluded.
Overall rating: Low certainty. Confidence in the effect estimate is limited. The true effect may be substantially different from the estimate.

§1.4What this extract does not establish

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences 2018;19(7):1987. doi:10.3390/ijms19071987 · PMID 29986520
  2. D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
  3. United States Pharmacopeial Convention. General Chapter ⟨788⟩ Particulate Matter in Injections. United States Pharmacopeia — National Formulary (USP–NF) 2024;USP 2024 Issue 1. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.